First Header Logo Second Header Logo

Connection

Steven Feldman to United States Food and Drug Administration

Back to Details
This is a "connection" page, showing publications Steven Feldman has written about United States Food and Drug Administration.
Steven Feldman
Connection Strength
0.771
United States Food and Drug Administration
  1. Li W, Ghamrawi R, Haidari W, Feldman SR. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. Ann Pharmacother. 2020 04; 54(4):380-387.
    View in: PubMed
    Score: 0.169
  2. Haidari W, Bruinsma R, Cardenas-de la Garza JA, Feldman SR. Sarecycline Review. Ann Pharmacother. 2020 02; 54(2):164-170.
    View in: PubMed
    Score: 0.167
  3. Kagha KC, Blauvelt A, Anderson KL, Leonardi CL, Feldman SR. A boxed warning for inadequate psoriasis treatment. Cutis. 2016 Sep; 98(3):206-207.
    View in: PubMed
    Score: 0.136
  4. Feldman SR. Inflammatory diseases: Integrating biosimilars into clinical practice. Semin Arthritis Rheum. 2015 Jun; 44(6 Suppl):S16-21.
    View in: PubMed
    Score: 0.123
  5. Feldman SR, Fleischer AB. Commentary on 'Indoor tanning injuries: an evaluation of FDA adverse event reporting data'. Photodermatol Photoimmunol Photomed. 2009 Aug; 25(4):221-2.
    View in: PubMed
    Score: 0.083
  6. Feldman SR. The design of clinical trials in psoriasis: lessons for clinical practice. J Am Acad Dermatol. 2003 Aug; 49(2 Suppl):S62-5.
    View in: PubMed
    Score: 0.055
  7. Shukla S, Feldman SR, Strowd LC. A safety review of the medications used to treat atopic dermatitis. Expert Opin Drug Saf. 2018 02; 17(2):179-183.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.